Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 1

Conditions

Recurrence 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 139Rituximab 115Etoposide 77Vincristine 75Doxorubicin 62Cytarabine 61Dexamethasone 58Prednisone 55fludarabine 52Methotrexate 46N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 42Lenalidomide 37Gemcitabine 35Radiotherapy 29Melphalan 27pegaspargase 22Prednisolone 22Ifosfamide 22fludarabine phosphate 20Busulfan 20Cisplatin 19Bendamustine Hydrochloride 19Asparaginase 18Peripheral Blood Stem Cell Transplantation 17ibrutinib 16Decitabine 16Carmustine 16Mercaptopurine 15Filgrastim 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × gemcitabine-oxaliplatin regimen × Lymphoid × Clear all
NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡